Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) --  Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market.

Read more at globenewswire.com